T = 296(2) K.
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The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
The title compound was synthesized according to a reported procedure. A mixture of 4-hydroxy-6-methylpyran-2-one (10 mmol), 3,4,5-trimethoxybenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was refluxed for 2−3 h and then cooled to room temperature. After filtering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under reduced pressure. *Corresponding author: Jing He, Department of Chemistry and Chemical Engineering, Shaanxi Xueqian Normal University, Xi'an, P.R. China, e-mail: jing_he3157@126.com 
Experimental details
H atoms bonded to C and N atoms were positioned geometrically and refined using a riding model, with C-H = 0.96 Å with U iso (H) = 1.2 times Ueq(C).
Discussion
Pyran derivatives may possess several types of pharmacological properties such as anticancer, anti-HIV, anticoagulant, spasmolytic, and antibacterial activity [5] . A large number of structurally novel pyran derivatives have been reported to show substantial cytotoxic activity in vitro and in vivo [6] . Research focused on the synthesis of the dihydropyran derivatives [7] . Herein, we reported the structure of a new pyran derivative. In the crystal structure of the title compound (cf. the figure), one methoxy group is connected to 4H,5H-pyrano [4, 3-b] pyran-5-one unit at the 7-position. One cyano group and one amino group are linked to the 2 and 4-position of this system, respectively. Three methoxy groups are connected to C13, C15 and C17 atoms respectively. Above mentioned bond lengths fall in their normal ranges compared with those in previously studies [8, 9] .
